CRIMSON BIOPHARM INC

Brookline, MA · Founded 2018 · Biotech · Private

CM93, a small-molecule EGFR tyrosine kinase inhibitor with enhanced blood-brain barrier penetration for glioblastoma treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Brookline, MA
Founded: 2018
Latest Form D: $1M, Oct 2019
Total capital: $1.4M

Federal grants: $400K; 1 award · 2023; Rank in peer group#166 of 326
Private capital raised: $1M; 1 Form D · last Oct 2019; 84 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 4 pending

Capital timeline

Latest events

May 2023Federal grantHealth and Human S · Phase I · Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration$400K
Oct 2019Private capital raisedForm D · SEC · 1st filing$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Linked publications#1 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Jean ZhaoResearcherDirectorLinked by $400K in grants as PI
Haiying PengExecutive Officer, DirectorNamed in SEC Form D filings
Thomas RobertsDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4

Sep 5, 2024Pending(1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL-ACRYLAMIDE Inhibitors Of Egfr For Use In The Treatment Of Brain TumorsUSPTOApplication 18573473
Jul 18, 2024PendingCrystalline Polymorphs Of Epidermal Growth Factor Receptor Inhibitor, And Compositions And Methods ThereofUSPTOApplication 18574248
PendingCrystalline Polymorphs Of Epidermal Growth Factor Receptor Inhibitor, And Compositions And Methods ThereofUSPTOApplication PCTUS2022036153

Show all 4 patent records

(1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL-ACRYLAMIDE Inhibitors Of Egfr For Use In The Treatment Of Brain TumorsSep 5, 2024 · Application 18573473Pending
Crystalline Polymorphs Of Epidermal Growth Factor Receptor Inhibitor, And Compositions And Methods ThereofJul 18, 2024 · Application 18574248Pending
Crystalline Polymorphs Of Epidermal Growth Factor Receptor Inhibitor, And Compositions And Methods ThereofApplication PCTUS2022036153Pending
Brain-selective Egfr Inhibitor For Cns DisordersApplication PCTUS2022034574Pending

Recent research by its founders

A disease model resource reveals core principles of tissue-specific cancer evolution20262 cites
Abstract 6794: The mouse cancer cell line atlas reveals core principles of tissue-specific cancer evolution20260 cites
Abstract LB232: BRCA1 deficiency programs a microglia-supported ferroptosis-resistant niche in breast cancer brain metastasis20260 cites

NATURA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
AMIDEBIO, LLCSimilar federal contract value in Biotech · null in contracts
Calder Biosciences Inc.Similar federal contract value in Biotech · null in contracts
TOSK, INC.Similar federal contract value in Biotech · null in contracts
Cyteir Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
AYANA BIO LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.